@article{d1d96bd1d31c415c91bcc6c1a14b4fbd,
title = "Cervical cancer prevention and control in women living with human immunodeficiency virus",
abstract = "Despite being highly preventable, cervical cancer is the fourth most common cancer and cause of cancer death in women globally. In low-income countries, cervical cancer is often the leading cause of cancer-related morbidity and mortality. Women living with human immunodeficiency virus (HIV)/acquired immunodeficiency syndrome are at a particularly high risk of cervical cancer because of an impaired immune response to human papillomavirus, the obligate cause of virtually all cervical cancers. Globally, approximately 1 in 20 cervical cancers is attributable to HIV; in sub-Saharan Africa, approximately 1 in 5 cervical cancers is due to HIV. Here, the authors provide a critical appraisal of the evidence to date on the impact of HIV disease on cervical cancer risk, describe key methodologic issues, and frame the key outstanding research questions, especially as they apply to ongoing global efforts for prevention and control of cervical cancer. Expanded efforts to integrate HIV care with cervical cancer prevention and control, and vice versa, could assist the global effort to eliminate cervical cancer as a public health problem.",
keywords = "Africa, cervical cancer, cytology, human immunodeficiency virus (HIV), human papillomavirus (HPV), low-income and middle-income countries (LMICs), prevention, screening, vaccination, visual inspection after acetic acid (VIA)",
author = "Castle, {Philip E.} and Einstein, {Mark H.} and Sahasrabuddhe, {Vikrant V.}",
note = "Funding Information: Disclosures: Mark H. Einstein was supported by the The AIDS Malignancy Consortium Grant (UM1CA121947) and the US-Latin American-Caribbean HIV/HPV-Cancer Prevention Clinical Trials Network Partnership Center Grant (U54CA242639) from the National Cancer Institute/National Institutes of Health. Philip E. Castle has received human papillomavirus tests and assays for research at reduced or no cost from Roche, Becton Dickinson, Cepheid, and Arbor Vita Corporation. Mark H. Einstein reports contracts from Johnson & Johnson, Pfizer, Inovio, AstraZeneca, and Merck (payment to institution for costs related to clinical trials); consulting fees from Papivax, Merck, PDS Biotechnologies, and Inovio (payment to institution for Dr. Einstein's time); unpaid committee work for the American Society for Colposcopy and Cervical Pathology and the Society of Gynecologic Oncology; and the National Cancer Institute and the World Health Organization provide payment for Dr. Einstein's time related to cervical cancer prevention. Vikrant V. Sahasrabuddhe had no disclosures. Funding Information: Mark H. Einstein was supported by the The AIDS Malignancy Consortium Grant (UM1CA121947) and the US‐Latin American‐Caribbean HIV/HPV‐Cancer Prevention Clinical Trials Network Partnership Center Grant (U54CA242639) from the National Cancer Institute/National Institutes of Health. Philip E. Castle has received human papillomavirus tests and assays for research at reduced or no cost from Roche, Becton Dickinson, Cepheid, and Arbor Vita Corporation. Mark H. Einstein reports contracts from Johnson & Johnson, Pfizer, Inovio, AstraZeneca, and Merck (payment to institution for costs related to clinical trials); consulting fees from Papivax, Merck, PDS Biotechnologies, and Inovio (payment to institution for Dr. Einstein's time); unpaid committee work for the American Society for Colposcopy and Cervical Pathology and the Society of Gynecologic Oncology; and the National Cancer Institute and the World Health Organization provide payment for Dr. Einstein's time related to cervical cancer prevention. Vikrant V. Sahasrabuddhe had no disclosures. Disclosures: Publisher Copyright: {\textcopyright} 2021 The Authors. CA: A Cancer Journal for Clinicians published by Wiley Periodicals LLC on behalf of American Cancer Society. This article has been contributed to by US Government employees and their work is in the public domain in the USA",
year = "2021",
month = nov,
day = "1",
doi = "10.3322/caac.21696",
language = "English (US)",
volume = "71",
pages = "505--526",
journal = "Ca-A Cancer Journal for Clinicians",
issn = "0007-9235",
publisher = "Wiley-Blackwell",
number = "6",
}